A prescriber can consider switching from semaglutide to tirzepatide when tirzepatide is appropriate for the condition being treated. The U.S. prescribing information for Zepbound advises against combining it with a GLP-1 receptor agonist such as semaglutide [3]. The prescriber can plan the change around the current product, side effects and other medicines.
What a prospective switch study found
The evidence on switching in the reverse direction comes from different studies. In a prospective 12-week study of 152 adults with type 2 diabetes, participants changed from a stable GLP-1 prescription to tirzepatide. Prior medicines included injectable semaglutide, dulaglutide and liraglutide [2].
Mean HbA1c declined by 0.43 percentage points and weight by 2.15 kg at week 12. These were overall changes from baseline across the prior medicines. The study did not include a group continuing semaglutide, so it cannot show how much of the change the switch itself added [2].
How prior use changed the comparison
In a separate observational study of people with type 2 diabetes, researchers checked for GLP-1 prescription fills in the previous six months. Those with prior fills lost 7.9 kg after starting tirzepatide and 3.7 kg after starting injectable semaglutide at 12 months. The corresponding changes among people without fills in that period were 10.2 kg and 6.1 kg [1].
The weight results used participants with both baseline and follow-up measurements. In the prior-use groups, that meant 296 on tirzepatide and 224 on semaglutide out of 5,577 matched participants per group. In the groups without prior use, 454 and 432 participants had both weights out of 10,702 per group [1].
What to discuss before a change
The GLP-1 insurance guide explains how coverage can depend on the product and diagnosis. If cost or availability is the issue, check coverage for the proposed prescription. Your prescriber can review your response, side effects and whether other diabetes medicines need closer monitoring[3].